Opinion|Videos|January 2, 2025
Clinical Decision-Making and Sequencing Strategies in EGFR-Mutated NSCLC
Panelists discuss how EGFR-targeted therapies differ in administration protocols and management strategies, with Palmer sharing tailored nursing interventions for oral tyrosine kinase inhibitors (TKIs) vs infusion or subcutaneous therapies, and Dr Scott addressing approaches to sequencing treatments, shared decision-making, and the role of resistance mechanisms and biopsy in guiding therapy decisions for EGFR-mutated advanced non–small cell lung cancer (NSCLC).
Advertisement
Video content above is prompted by the following:
- How do the various EGFR-targeted therapies differ in terms of administration protocols and the strategies employed for effective patient management?
- How do you tailor nursing interventions for patients on oral TKIs vs those receiving infusion or subcutaneous therapies, especially in managing adverse effects and ensuring adherence?
- What strategies do you employ to facilitate open communication with patients about what to expect during their treatment and to address their concerns effectively?
- How do you approach the sequencing of therapies across multiple lines of treatment in EGFR-mutated NSCLC? How do you approach shared decision-making and patient education when discussing treatment options for EGFR-mutated NSCLC?
- What factors influence your decision-making when moving from one line of therapy to the next?
- How do resistance mechanisms impact your sequencing strategy, and what role does biopsy play in guiding these decisions?
Advertisement
Related to this article
In a prospective cohort, a 3-gene blood model predicted 1-year castration resistance with an AUC of 0.89 in metastatic hormone-sensitive prostate cancer.
Rutika Mehta, MD, MPH, explains how she sequences MSI, HER2, claudin 18.2, and PD-L1 testing when tissue is limited in gastroesophageal cancer.
Dirk Schadendorf, MD, outlineed which patients with BRAF V600–mutant melanoma, including those with brain metastases, may be candidates for triplet therapy.
Dirk Schadendorf, MD, discussed final STARBOARD data with encorafenib, binimetinib, and pembrolizumab and its role in BRAF V600–mutant melanoma care.
Heath Skinner, MD, PhD, discussed the 3 considerations that determine which new radiation oncology service lines his network chooses to build.
Dwight H. Owen, MBBCh, MS, discussed why severe immune-related toxicities remain hard to predict as immunotherapy combinations expand in lung cancer.
Mingjia Li, MD, discussed the limitations of current biomarkers in selecting patients with resectable NSCLC for neoadjuvant chemoimmunotherapy.
Heath Skinner, MD, PhD, discussed which new radiation oncology service lines community practices can implement, how leadership decides, and what launches require.
Advertisement
Advertisement
Trending on CancerNetwork
1
Predicting Severe Immune-Related Toxicities in Lung Cancer Immunotherapy
2
Blood mRNA Model Predicts Castration Resistance in Metastatic Prostate Cancer
3
CD19 CAR T Cell Therapy for Treatment-Refractory Seropositive Rheumatoid Arthritis: A Phase 1 Trial
4
Outpatient Treatment-Related Toxicity After Hospital Discharge Among Patients Receiving Lifileucel for Advanced Melanoma
5